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This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).SUMMARYInducedpluripotent stem cells (iPSCs) hold great potential not only for humanbut also for veterinary purposes. The equine industrymust
often deal with health issues concerning muscle and cartilage, where comprehensive regenerative strategies are still missing. In this re-
gard, a still open question is whether equine iPSCs differentiate towardmuscle and cartilage, andwhether donor cell type influences their
differentiation potential.We addressed these questions through an isogenic system of equine iPSCs obtained frommyogenicmesoangio-
blasts (MAB-iPSCs) and chondrogenic mesenchymal stem cells (MSC-iPSCs). Despite similar levels of pluripotency characteristics, the
myogenic differentiation appeared enhanced inMAB-iPSCs. Conversely, the chondrogenic differentiationwas augmented inMSC-iPSCs
throughboth teratoma and in vitro differentiation assays. Thus, our data suggest that equine iPSCs can differentiate toward themyogenic
and chondrogenic lineages, and can present a skewed differentiation potential in favor of the source cell lineage.INTRODUCTION
Horses are invaluable animals for companionship and
sport. The equine industry creates an estimated economic
impact of US$300 billion worldwide, and novel means for
addressing equine health issues are constantly required
(Tecirlioglu and Trounson, 2007). Musculoskeletal prob-
lems, including pathologies or injuries of muscle and carti-
lage, constitute a leading health threat among horses
(Smith et al., 2014). As an example, equine atypical myop-
athy has been increasingly reported over recent years (Vo-
tion and Serteyn, 2008), and equine osteochondrosis is
relatively frequent across different breeds (van Weeren
and Jeffcott, 2013). Therefore, the quest for novel tools
for muscle and cartilage repair is still compelling. In this
regard, stem cells may support the needs of veterinary
medicine (Cebrian-Serrano et al., 2013). In equine prac-
tice, mesenchymal stem cells (MSCs) are commonly used
to treat tendinitis and osteoarthritis (Schnabel et al.,
2013). However, a comprehensive regenerative approach
tailored to both muscle and cartilage is still missing, espe-
cially for large-scale applications. Importantly, considering
the obvious difficulties of in vivo trials, in vitro models
constitute a useful, first-line trial platform for addressing
differentiation and heterogeneity of stem cells (Goodell
et al., 2015). To this end, induced pluripotent stem cellsStem(iPSCs) hold great potential, in light of their tremendous
expansion capacity and wide differentiation potential (Ya-
manaka, 2009). Recently, iPSCs have been generated from
equine fibroblasts (Breton et al., 2013) and keratinocytes
(Sharma et al., 2014); however, their differentiation poten-
tial toward myocytes or chondrocytes remains unknown.
Furthermore, iPSCs tend to retain, at least partially, the
intrinsic fate propensity of the cell source (Sanchez-Freire
et al., 2014). In mice, iPSCs derived from resident
myogenic pericytes, i.e. mesoangioblasts (MABs), show
biased myogenic differentiation in both teratoma and
in vitro differentiation assays (Quattrocelli et al., 2011).
However, it is still unknown whether it is possible to
discriminate the intrinsic equine iPSC propensity toward
the myogenic and the chondrogenic lineages. To address
this question, isogenic settings need to reduce the vari-
ability introduced by genetic background (Kotini et al.,
2015). Relevantly for putative veterinary applications,
the choice of the cell source should be confined to somatic
compartments at facilitated reach, e.g. blood and superfi-
cial muscle biopsies. Equine peripheral blood has been
recently used to isolate circulating progenitors, exhibiting
MSC properties (Spaas et al., 2013) and differentiating in
chondrocytes (Broeckx et al., 2014). With regard to the
muscle, it is still unknown whether equine MABs can be
isolated with similar characteristics to murine, canine, orCell Reports j Vol. 6 j 55–63 j January 12, 2016 j ª2016 The Authors 55
human MABs (Quattrocelli et al., 2014; Sampaolesi
et al., 2006), and to which extent equine MABs display
myogenic propensity, once cultured in vitro and after
reprogramming.
Thus, the objective of this study is to compare iPSCs
obtained from equine MABs and peripheral blood MSCs
in isogenic conditions to evaluate the intrinsic iPSC pro-
pensity for myogenic and chondrogenic lineages.RESULTS
To obtain source cells for reprogramming in isogenic set-
tings (Figure 1A), we isolated equine MABs in isogenic set-
tings with MSC lines, which were already established from
peripheral blood (Spaas et al., 2013), and demonstrated
chondrogenic commitment (Broeckx et al., 2014). We
adapted the procedures that were previously reported for
murine and human MABs (Quattrocelli et al., 2012) to bi-
opsies obtained from the splenius muscles of three synge-
neic horses, and accordingly sorted the heterogeneous cell
population for alkaline phosphatase (AP) (1.5% ± 0.6%
[mean ± SD; n = 3]). AP activity was confirmed in the
AP+ but not the AP fraction (Figure 1B). At early passage
(<3), AP+ cells proliferated with a doubling time of approx-
imately 27 hr and stained positively for NG2, CD140a,
CD140, and CD44, pericytic surface markers reported
for murine and human MABs (Quattrocelli et al., 2012)
(Figure 1C). Furthermore, after 7 days in serum starva-
tion, the AP+ cells robustly differentiated into multinucle-
ated, MyHC+ myotubes (fusion index, 27.5% ± 7.01%
[mean ± SD; n = 3]), unlike the isogenic MSC controls (Fig-
ure 1D). We thus identified the AP+ cells as bona fide
equine MABs, which show robust myogenic propensity
compared with the isogenic MSCs. To obtain iPSCs, we
transduced equine isogenic MABs and MSCs with retro-
viral vectors carrying human reprogramming factors
(OCT4, SOX2, KLF4, cMYC), then picked and expanded
single-cell clones (n = 3/cell type) on a feeder layer. Re-
programming efficiency was approximately 0.0001% for
both cell types. Colonies of both MAB- and MSC-iPSCs ap-
peared round-shaped and with compact borders, and were
positive for AP, OCT4, SOX2, NANOG, and LIN28 staining
(Figure 1E). The expression of the pluripotency markers
OCT4, SOX2, NANOG, and LIN28 was confirmed with spe-
cifically cross-reacting primers, using human H9 cells as
positive control. Moreover, expression of retroviral trans-
genes was not detected in both equine iPSC types (Fig-
ure 1F). Also, equine iPSCs showed a euploid, donor-
matching karyotype (n = 62, XX; Figure 1G). Furthermore,
after 20 days of spontaneous in vitro differentiation, both
MAB- and MSC-iPSCs differentiated in ectodermal
(TUJ1+), endodermal (aFP+), and mesodermal (aSMA+) de-56 Stem Cell Reports j Vol. 6 j 55–63 j January 12, 2016 j ª2016 The Authorrivative cells (Figure 1H). Thus, equine isogenic MAB- and
MSC-iPSCs shared common markers of pluripotency. To
gain insight into iPSC intrinsic propensity, we subcutane-
ously injected equine iPSCs in immunodeficient mice and
analyzed the teratomas at 4–6 weeks after injection. Both
iPSC types generated teratomas containing immature de-
rivatives of ectoderm, endoderm, and mesoderm, confirm-
ing their pluripotency (Figure 2A). However, MAB-iPSC
teratomas showed a significantly higher quantity of
immature muscle patches in comparison with MSC-iPSCs
(Figure 2B). Conversely, MSC-iPSC teratomas showed
significantly larger chondrogenic patches (Figure 2C). To
exclude the contribution of host cells to teratoma deriva-
tives, we stained equine iPSC teratoma sections for lamin
A/C, using murine iPSC- and human iPSC-derived tera-
tomas as negative and positive controls, respectively.
Both MAB- and MSC-iPSC-derived teratomas stained posi-
tively to lamin A/C (Figures 2D and 2E), indicating that
the teratoma tissues derived from equine iPSCs. Intrigued
by the propensities shown in the teratoma assays, we
asked whether the source-related propensity was signifi-
cantly skewing the iPSC fate in dedicated differentiation
assays. We tested the myogenic differentiation of iPSCs
and related source cells under conditions of bone
morphogenetic protein (BMP)/transforming growth factor
b (TGF-b) blockade and assayed for MyHC+ myocytes and
myotubes. After 30 days, MABs and MAB-iPSCs showed
higher differentiation rates compared with isogenic
MSCs and MSC-iPSCs (Figures 3A and 3B). Moreover,
equine MYH2 expression levels were significantly higher
in differentiated MABs and MAB-iPSCs (Figure 3C).
We then tested the chondrogenic differentiation in com-
pacted spheres (Spaas et al., 2013) and assayed for Alcian
blue-positive structures. Only MSC- and MSC-iPSC-
derived spheres showed consistent chondrogenic differen-
tiation, assayed as larger chondrogenic patches and lower
cell density when compared with undifferentiated spheres
(Figures 4A and 4B). Accordingly, equine COMP expression
levels were significantly induced only in differentiated
MSC and MSC-iPSC spheres, and appeared non-detectable
in MABs and MAB-iPSCs (Figure 4C). Furthermore, in light
of the adipogenic potential of equine MSCs (Spaas et al.,
2013), we tested the differentiation efficiency of equine
iPSCs toward the adipogenic lineage. Intriguingly, albeit
generally limited and variable, the differentiation effi-
ciency into Oil Red+ adipocytes appeared higher in
MSC-iPSCs than in MAB-iPSCs (Figure 4D), indicating
a possible retention of MSC propensity toward other
lineages as well. Thus, in both teratoma and in vitro
assays, equine isogenic iPSCs showed intrinsic, discrimi-
nable propensities toward the lineages of source stem
cells, e.g. myogenic in MAB-iPSCs and chondrogenic in
MSC-iPSCs.s
Figure 1. Generation of Equine MAB- and
MSC-iPSCs in Isogenic Conditions
(A) Schematic experimental plan.
(B) AP activity staining on AP+ (positive
signal) and AP (background signal) cell
fractions from the skeletal muscle.
(C) Immunofluorescence staining for peri-
cytic markers and related isotypes of equine
MABs (AP+ cells).
(D) MyHC immunofluorescence staining of
equine MABs and MSCs after serum starva-
tion. Myogenic differentiation is apparent as
multinucleated myotubes.
(E) Panel of pluripotency characterization
for equine iPSCs.
(F) (Left) RT-PCR with specifically cross-re-
acting (equine-human) primers (eq-, nega-
tive equine control, parental cells; hu+,
human positive control, H9 ESCs; rt-,
negative control of reverse transcription).
(Right) RT-PCR for expression of retroviral
(retrov-) reprogramming factors (ct+, posi-
tive control, fibroblasts freshly transduced
with the reprogramming retroviruses).
(G) Euploid karyograms of equine iPSCs at
passage 3.
(H) Immunofluorescence analysis for
markers of ectodermal (TUJ1+), endodermal
(aFP+), and mesodermal (aSMA+) derivative
cells after spontaneous iPSC differentiation.
All results shown were obtained from cell
clones from all three donors (n = 3 inde-
pendent experiments/cell type).
Scale bars, 100 mm.DISCUSSION
Inconsistencies among cell source isolation and reprog-
ramming techniques can result in iPSCs that may appear
similar, but have very different capacities to modulate or
contribute to tissue regeneration (Bar-Nur et al., 2011; Hi-
ler et al., 2015). In addition, several studies on the epige-
netic variations in iPSCs have raised concerns that theseStemdissimilarities may compromise the clinical applications
of iPSCs (Shtrichman et al., 2013). Our data indicate that
source-related intrinsic propensity is retained in iPSCs,
and quantitatively primes their differentiation toward
skeletal muscle and cartilage lineages. The iPSCs used in
our study were obtained with human reprogramming fac-
tors, and appeared genuinely reprogrammed as equine
endogenous genes were reactivated (NANOG, LIN28) andCell Reports j Vol. 6 j 55–63 j January 12, 2016 j ª2016 The Authors 57
Figure 2. Equine iPSC Intrinsic Propen-
sities to Muscle and Cartilage Derivatives
in Teratomas
(A) Representative pictures of derivatives
(arrowheads) of ectoderm (upper, ecto-
dermal cysts; lower, neural tube), endoderm
(unstructured, gland-like acinar tissues), and
mesoderm (upper, adipose tissue; lower,
immature bone structures).
(B) Quantitation of striated muscle patches
(white arrows) by means of Masson trichrome
staining (*p < 0.05, Mann-Whitney U test,
n = 3 independent experiments per cell type).
(C) Quantitation of chondrogenic patches
(black arrows) by means of Alcian blue
staining (*p < 0.05, Mann-Whitney U test,
n = 3 independent experiments per cell type).
(D) Immunofluorescence staining for lamin
A/C on equine iPSC teratomas (n = 4/cell
type; ct-, negative control, murine iPSC
teratoma; ct+, positive control, human iPSC
teratoma).
(E) Staining for lamin A/C and markers
of ectodermal (TUJ1), endodermal (aFP),
and mesodermal (SARCaACT) derivatives in
equine MAB-iPSC-derived teratomas (n = 4
technical replicates per cell type). Magnifi-
cations of highlighted fields are shown to
the right of original panels to evidence
co-localization of lamin A/C (nuclear mem-
brane) and the cytoplasmic markers. Com-
parable results were obtained with MSC-iPSCs
(data not shown).
Histograms represent average values; error
bars indicate SD. Scale bars, 100 mm.retroviral transgenes were silenced. Albeit far from
comprehensive, the pluripotency characterization of our
cells is consistent with that of other equine iPSC lines pre-
viously reported by independent groups (Breton et al.,
2013; Sharma et al., 2014). However, a more translation-
ally relevant insight is expected when non-integrative vec-
tors carrying the equine ortholog factors will be available.
Xeno-free conditions for reprogramming and expansion58 Stem Cell Reports j Vol. 6 j 55–63 j January 12, 2016 j ª2016 The Authorwill be necessary also for properly addressing the dura-
bility of such propensity (our studies are limited to passage
8 after clone isolation). Such a strategy will indeed allow
more refined studies, including epigenetic analyses. In
this regard, our in vitro data support the notion that not
all epigenetic signatures of parental stem cells are equally
erased during reprogramming, thus altering the differenti-
ation efficiency of iPSCs. The effects appeared relevant fors
Figure 3. Assessment of Equine iPSC
Myogenic Differentiation
(A) Immunofluorescence staining for MyHC
of parental cells and iPSCs under BMP/TGF-b
blockade.
(B) Quantitation of differentiation efficiency
as fraction of cells participating to nascent
MyHC+ myotubes (fusion index; *p < 0.05,
one-way ANOVA with Bonferroni comparison,
n = 3 independent experiments per cell type).
(C) qRT-PCR with equine-specific MYH2
primers; data are depicted as fold change
versus MABs or MAB-iPSCs (AU, arbitrary
units; *p < 0.05, unpaired t test, n = 3 in-
dependent experiments per cell type). Both
analyses revealed higher myogenic pro-
pensity in MAB-iPSCs than in MSC-iPSCs (n = 3
independent experiments per cell type).
Histograms represent average values; error
bars indicate SD. Scale bars, 100 mm.myogenic and chondrogenic lineages. Our results showing
enhanced differentiation with equine iPSCs seem consis-
tent with the findings previously reported with murine
MAB-iPSCs (Quattrocelli et al., 2011) and human reprog-
rammed chondrocytes (Borestrom et al., 2014). In this
regard, an important issue to be considered is that we
reprogrammed MABs and MSCs, and not differentiated
cells, i.e. myocytes and chondrocytes. This was based on
clinical and experimental reasons. From a translational
perspective for iPSC applications, stem cells are likely
superior to terminally differentiated progenies, due to
greater expansion ability and higher susceptibility to
reprogramming protocols (Cai et al., 2010). Moreover,
MABs and MSCs are currently under clinical trial scrutiny
in human patients for the treatment of muscle
(EudraCT#2011-000176-33) and cartilage conditions (US-
CT#NCT01879046). Also, our attempts to reprogram the
differentiated progenies of equine MABs and MSCs failed
(data not shown), likely due to very low transduction effi-Stemciency and halted proliferation. Importantly, as shown
by the results of parallel differentiation of parental cells
and iPSCs, MAB- and MSC-iPSCs efficiently retained the
myogenic and chondrogenic differentiation biases, respec-
tively. However, it remains unknown whether MSCs from
other body regions (e.g. bone marrow, adipose tissue) will
exhibit different levels of chondrogenic bias and reprog-
ramming potency. Furthermore, our results for the adipo-
genic lineage, although limited to the iPSC pools, suggest
that other differentiation propensities might be retained
too, albeit likely with different efficiencies. Dedicated
studies are needed to address this point, as the purpose
of our study was centered on muscle and cartilage. In
conclusion, the observations reported here hint at further
studies of in vivo/in vitro differentiation, possibly in com-
bination with known genetic defects and tailored correc-
tions, in order to better harness the potential of equine
iPSCs for veterinary disease modeling and regenerative
medicine.Cell Reports j Vol. 6 j 55–63 j January 12, 2016 j ª2016 The Authors 59
Figure 4. Assessment of Equine iPSC Chondrogenic Differen-
tiation
(A) Alcian blue staining for undifferentiated and chondrogenic
microspheres. Indicated percentages refer to the Alcian blue-
positive areas (arrows) across the depicted spheres.
(B) Quantitation of cell density and differentiation efficiency in
parental cells and iPSCs, comparing undifferentiated (undiff) and
differentiated (chondro) spheres (*p < 0.05, one-way ANOVA with
Bonferroni comparison; ns, not significant).
(C) qRT-PCR with equine-specific COMP primers; data are depicted
as fold change versus undiff (AU, arbitrary units; nd, not detect-
able; *p < 0.05, one-way ANOVA with Bonferroni comparison; n = 3
independent experiments [3 technical replicates per experiment/
cell type]).
(D) Oil Red staining on MAB- and MSC-iPSCs after adipogenic
differentiation (red lipid vacuoles denote adipocyte-like cells).
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Cell Isolation and Expansion
All procedures involving live horses were performed under the
specifications of the Ethical Approval Forms EC_2012_001 for
blood withdrawal and EC_2014_003 for muscle tissue sampling
(Ethics Committee, Global Stem Cell Technology). Equine
MABs were isolated from three syngeneic female siblings of the
French trotter breed aged between 5 and 7 years. Splenius muscle
biopsies were taken in sterile conditions under local anesthesia,
and equine MABs were isolated using previously reported proce-
dures for murine and human MABs (Quattrocelli et al., 2012).
In brief, muscle biopsy pieces (approximately 2 3 2 3 2 mm)
were cultured on collagen (Sigma-Aldrich)-coated dishes
(NUNC) and MABs were isolated as AP+-sorted population from
the outgrowths. Peripheral blood MSCs from the same horses
were already isolated and characterized (Spaas et al., 2013).
Equine MABs were then passaged and expanded on collagen-
coated culture vessels (NUNC) in IMDM10% medium (IMDM
supplemented with 10% FBS, 1% penicillin-streptomycin [pen/
strep], 1% L-glutamine, 1% sodium pyruvate, 1% non-essential
amino acids [NEAA], 1% insulin-transferrin-selenium supplement
[Thermo Fisher], 0.2% 2-mercaptoethanol, and 5 ng/ml basic
fibroblast growth factor [bFGF; Peprotech]) at 5% O2/5% CO2
and 37C. Equine MSCs were passaged and expanded on tissue
culture vessels (NUNC) in DMEM10% medium (DMEM supple-
mented with 10% FBS, 1% pen/strep, 1% L-glutamine, and 1%
sodium pyruvate) at 5% O2/5% CO2 and 37
C. Equine cells
were reprogrammed analogously to procedures described for mu-
rine iPSCs (Quattrocelli et al., 2011). In brief, cells were trans-
duced with retroviral particles carrying human OCT4, SOX2,
KLF4, and CMYC cDNA sequences (pMX vectors, Addgene) and
seeded at low confluence on a feeder layer of mitomycin-treated
primary murine embryonic fibroblasts (iMEFs). Reprogramming
efficiency was calculated as percentage of ESC-like colonies versus
starting cell number prior to transduction. Equine iPSC colonies
were picked at 4–5 weeks after transduction, clonally expanded,
and characterized for pluripotency marker expression. Equine
MAB- and MSC-iPSCs were cultured on a feeder layer of iMEFs
in equine iPSC medium (DMEM-F12 with Nutrient mix and
HEPES, supplemented with 20% KnockOut serum, 1% pen/strep,




The myogenic propensity of somatic MABs and MSCs was tested
in serum starvation conditions, i.e. in DMEM2% medium (high-
glucose DMEM supplemented with 2% horse serum [Thermo
Fisher], 1% pen/strep, and 1% L-glutamine) for 7 days. Fusion in-
dex was calculated as the percentage of nuclei enclosed inDifferentiation rate is quantitated as percentage of adipocytes per
field (*p < 0.05, Mann-Whitney U test, n = 3/cell type, n = 3 in-
dependent experiments per cell type).
Histograms represent average values; error bars indicate SD. Scale
bars, 100 mm.
s
myotubes per field. For myogenic differentiation, iMEF-deprived
iPSCs were seeded at 4,000 cells/cm2 on gelatin (Millipore)-coated
vessels, and kept in F12-20% medium (DMEM-F12 with Nutrient
mix and HEPES, supplemented with 20% FBS, 1% pen/strep, 1%
NEAA, and 0.2% 2-mercaptoethanol) for 20 days. Cells were then
reseeded at 4,000 cells/cm2 on gelatin-coated vessels and kept in
F12-20% medium, supplemented with 1% insulin-transferrin-
selenium (ITS) supplement (Thermo Fisher), for 15 days. Terminal
myogenic maturation was achieved in DMEM2% medium, sup-
plemented with 1% ITS, 50 ng/ml recombinant human NOGGIN
(BMP inhibitor; Thermo Fisher), and 1 mM SB431542 hydrate
(TGF-b inhibitor; Sigma-Aldrich) for 15 days. All aforementioned
differentiation assays were performed at 5% O2/5% CO2 and
37C. To initiate chondrogenic differentiation, 3 3 105 cells
were resuspended in 5 ml of medium and centrifuged for 5 min
at 150 3 g. Subsequently, 0.5 ml of chondrogenic differentiation
medium (basal differentiation medium [Lonza] supplemented
with 10 ng/ml TGF-b3 [Sigma]) or expansion medium were added
per pellet and refreshed twice a week. Four chondrospheres and
four undifferentiated control spheres were established per cell
type per horse, and evaluated after 10 days with Alcian blue stain-
ing and PCR. Adipogenic differentiation was induced with the
Mesenchymal Adipogenesis Assay (Millipore) on plated embryoid
bodies after cell sprouting (>95% confluence). The manufacturer’s
instructions were followed for differentiation cocktails, timing,
and staining.
Teratoma Assay
All procedures involving live mice were performed under the spec-
ifications of the Ethical Approval #P150/2014 (Ethics Committee,
KU Leuven). Immunodeficient 2-month-old Rag2-null/Il2rg-null
mice were injected with a 100-ml suspension of 350,000 equine
iPSCs in 1:2 diluted Matrigel (Thermo Fisher) subcutaneously
in the nape region. Teratomas (n = 3/iPSC type) were retrieved
between 4 and 6 weeks after injection, when visible and not yet
ulcerated.
Immunofluorescence, Histological, and Colorimetric
Staining
Immunofluorescence staining was performed following the
commonly used steps of Triton-based (Sigma-Aldrich) permeabili-
zation (avoided for MAB surface marker staining), background
blocking with donkey serum (Sigma-Aldrich), overnight incuba-
tion with primary antibody at 4C, 1 hr of incubation with
1:500 AlexaFluor-conjugated donkey secondary antibodies
(Thermo Fisher), and final counterstain with Hoechst. Here fol-
lows the list of primary antibodies and relative dilutions: mouse
anti-NG2 PE-conjugated (R&D Systems #MAB6689), 1:100;
mouse anti-CD140a and anti-CD140b APC-conjugated (Anti-
bodies Online #ABIN910520/ABIN457302), 1:50; mouse anti-
CD44 APC-conjugated (eBioscience #17-0441-81), 1:200; goat
anti-OCT4 (Abcam #ab19857), 1:500; goat anti-SOX2 (Santa
Cruz #sc-17320), 1:100; rabbit anti-Nanog (Abcam #ab80892),
1:500; goat anti-Lin28 (Santa Cruz #sc-54032), 1:100; mouse
anti-MyHC (DSHB, #MF20), 1:8; rabbit anti-TUJ1 (Millipore
#04-1049), 1:300; rabbit anti-aFP (Abcam #ab87635), 1:500;
mouse anti-aSMA (Sigma-Aldrich #A2547), 1:300; mouse anti-Stemlamin A/C (Millipore #05-714), 1:100. Histological staining
(H&E and Alcian blue, reagents from Roche-Ventana; Masson tri-
chrome, reagents from Sigma-Aldrich) was performed on 5-mm-
thick slices from paraffin-embedded tissue pieces following the
manufacturer’s instructions. AP staining was performed exposing
2% PFA-fixed cells to the BCT/NBT reagent (Sigma-Aldrich; resus-
pended in dH2O) for 1 hr. Quantitation of myogenic differentia-
tion was performed on at least ten independent fields per cell
type. Quantitation of teratoma derivatives and chondrogenic dif-
ferentiation of the microspheres was performed on at least ten se-
rial sections (approximately 100-mm interval between consecutive
sections).Molecular Assays
For pluripotency marker expression, 1:5 diluted cDNA was ob-
tained from 1 mg of total RNA (SSIII cDNA production kit and
RNA extraction kit from Thermo Fisher). RT-PCR was performed
using Taq polymerase-associated reagents (Thermo Fisher) and
conditions (95C 30 s, 60C 30 s, 72C 60 s; 403 for endogenous,
253 for retroviral genes). Primers: OCT4 Fw GAGGCTCTGCAGC
TCAGTTT, Rev CTCCAGGTTGCCTCTCACTC; SOX2 Fw AAC
CAGCGCATGGACAGTTA, Rev GACTTGACCACCGAACCCAT;
NANOG Fw ATACCTCAGCCTCCAGCAGA, Rev AGCCCCGG
GTAGTCTGTAGT; LIN28 Fw TGTAAGTGGTTCAACGTGCG,
Rev CAGCTTACTCTGGTGCACAA; PGK Fw CTGGGCAAG
GATGTTTTGTT, Rev TATTTTGGCTGGCTCAGCTT; retrov-OCT4
Fw CCCCAGGGCCCCATTTTGGTACC; retrov-SOX2 Fw GGCACC
CCTGGCATGGCTCTTGGCTC; retrov-KLF4 Fw ACGATCGTGG
CCCCGGAAAAGGACC; retrov-cMYC Fw CAACAACCGAAAATG
CACCAGCCCCAG; pMX Rev (for all retrov-primers) TTATCGT
CGACCACTGTGCTGCTG. MYH2 qRT-PCR was performed by
means of SybrGreenmix (Thermo Fisher) using the Viia7 384-plate
reader (Thermo Fisher; final primer concentration, 100 nM; final
volume, 10 ml; PGK, internal reference; thermal profile, 95C
15 s, 60C 60 s, 403). Primers: MYH2 Fw TGAGTCCCAGGTCA
ACAAGC, Rev TTCCATAGCGTGAAGGCATGA. For the COMP
qRT-PCR assay, total RNA (totRNA) was isolated with the High
Pure Isolation Kit (Roche Diagnostics). TotRNA integrity was eval-
uated using the Agilent 2100 Bioanalyzer (Agilent Technologies;
RIN values, 8.8–10). TotRNA was reverse transcribed with the
iScript cDNA Kit (Bio-Rad). qRT-PCR assay for COMP and reference
genes SDHA andACTB (selectedwith geNorm)was performedwith
FastStart essential DNA Green Master (Roche Diagnostics) on the
LightCycler 480 (Roche) with following cycling conditions: 20 s
at 95C, 40 s at annealing temperature (sdha, 59C; actb, comp,
60C), 1 min at 72C, 453. SDHA, ACTB primers: see De Schauwer
et al., 2014. COMP primers: Fw GACTACGCGGGCTTCATCTT,
rev CTGCTCCATCTGCTTCCACA. Specificity was proved through
melting curve analysis. Expression levels were analyzed and
normalized using qBase+ (version 3.0). Assays were performed
according to the MIQE guidelines (Bustin et al., 2009).Statistical Analysis
Power analysis was performed using Sample Size Calculator
(power, 0.80; alpha, 0.05). Statistical tests were chosen based on
data distribution. For teratoma derivatives, the Mann-Whitney
U test was applied (p < 0.05). For MYH2 levels, the unpaired t testCell Reports j Vol. 6 j 55–63 j January 12, 2016 j ª2016 The Authors 61
was applied (p < 0.05). For myogenic efficiency, chondrogenic
efficiency, COMP levels, and cell density, one-way ANOVA with
Bonferroni multi-comparison was applied (p < 0.05). All tests
were performed by means of Prism v5.0 (GraphPad).ACKNOWLEDGMENTS
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